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Diverse functions of microRNAs have been investigated in tumorigenesis in osteosarcoma (OS), involving
the regulation of proliferation, invasion, migration, apoptosis and drug resistance. MiR-367 was found to
be an oncogene and increased in OS. However, the function of miR-367 in drug resistance in OS cells is
still unknown. In this study, we found that miR-367 was up-regulated in OS tissues and OS cell cultures.
Meanwhile, treatment with adriamycin (ADR) induced apoptosis of OS cells with upregulation of miR-
367. Notably, KLF4 was demonstrated to be a direct target of miR-367 by gene reporter assay, and miR-
367 signiﬁcantly blocked both mRNA and protein level of KLF4. In addition, overexpression of miR-367
markedly suppressed the increase of KLF4 induced by ADR in OS cells, as well as Bax and cleaved cas-
pase-3, which were signiﬁcantly reversed by anti-miR-367 transfection. Taken together, our data de-
monstrates that miR-367 and KLF4 play important roles in OS treatment and ADR resistance, suggesting
that miR-367 is a potential biomarker of chemotherapy resistance in OS and also probably a novel
therapeutic target against OS.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma (OS) is the most common type of bone tumor
occurred in adolescents and children [1]. OS is highly malignant
and accounts for about half of bone sarcomas with high potential
of metastasis [2]. Treatment for OS is mainly depended on surgical
operation, assisted with chemotherapy [3]. However, even with
multiple chemotherapies, it is still less optimistic due to the poor
5-year survival rates of OS, regardless of increasing kinds or do-
sages of chemotherapeutic drugs [4]. Recently, drug resistance in
OS has draw more attention in understanding the molecular me-
chanism in OS treatement [5]. However, it is still an ongoing
progress in discovering and developing novel therapeutic target.
microRNAs (miRNAs) are non-coding RNAs with 17–25 nu-
cleotides [6,7]. As is known, miRNAs have diverse functions in
multiple physiological progression [8–10]. Since the initiation,
more than 1000 miRNAs have been found to regulate the devel-
opment and progression in human diseases and tumorigenesis
[11–14]. miRNAs regulate the target genes at the post-transcrip-
tional level by binding with 3′ untranslated region. Recently,
growing evidence showed that the dysfunction and dysregulationGmbH. This is an open access art
d equally to this work.of miRNAs resulted in the occurrence and development of tumor
[15–17]. In OS, multiple miRNAs had showed differential expres-
sion between tumor tissues and normal counterparts, and some
had been veriﬁed to be involved with drug resistance [18,19].
miR-367 has been recognized to be a tumor suppressor gene in
gastric cancer by inhibiting invasion and metastasis via regulating
Rab23 [20]. On other hand, miR-367 also functioned as an onco-
gene in pancreatic ductal adenocarcinoma by promoting epithe-
lial-to-mesenchymal transition through the Smad7-TGF-beta sig-
naling pathway [21]. Thus studies showed the diverse functions of
miR-367 in different tumorigenesis. However, little is known about
the functions of miR-367 in OS and in drug resistance.
In this study, we focused on the function of miR-367 in drug
resistance in OS. We found that the expression of miR-367 in-
creased in human OS tissues and OS cell lines. Meantime, down-
regulation of miR-367 participated in apoptosis induced by
adriamycin (ADR), a classical drug in OS chemotherapy. Further
investigations demonstrated that KLF4 was a direct target of miR-
367, which was involved in the ADR induced apoptosis. Further-
more, overexpression of miR-367 promote the resistance to ADR in
OS cells, by decreasing the expression of KLF4, Bax and Cleaved
Caspase-3. Our study suggested that miR-367 could be a bio-
marker of the chemoresistance in OS treatment, and miR-367
could be a potential target in clinical OS therapies.icle under the CC BY-NC-ND license
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2.1. Patients and tissues
The human osteosarcoma tissues were obtained from 40 pa-
tients underwent standard surgery within 2009–2014 at depart-
ment of Orthopedics, Changhai hospital (the Second Military
Medical University). The counterparts were obtained 5 cm away
from the tumor tissues at the same time. All of the tumor tissues
and counterparts were put into liquid nitrogen immediately post-
operation for the following examinations. None of the patients had
received thermotherapy or radiotherapy before the surgery. The
histologic responses were evaluated by professional pathologists
in our hospital. The research progress was conducted according to
the Declaration of Helsinki of the World Medical Association.2.2. Cell cultures and drug administration
The human OS cell lines MG-63, U2OS, Saos-2 and normal os-
teoblastic cell line HOB (ATCC) were cultured in dilbecco modiﬁed
eagle medium (DMEM) (Hyclone) with 10% fetal bovine serum
(Gbico), 100 U/ml penicillin and 100 U/ml streptomycin at 37 °C in
5% CO2 incubators. 0.4 μg/ml of ADR was administrated in cells for
6, 12, 24 h, respectively. The cells were harvested and store at
80 °C before analysis after drug treatment for further analysis.
2.3. Quantitative PR-PCR
The isolation of RNA from tumor tissues and the counterparts was
conducted using Trizol reagent (Takara, Tokyo, Japan). The reverse
transcription with oligo (dT) priming (Toyobo) was performed to
generate complementary DNAs (cDNAs). Level of miRNA was per-
formed using quantitative RT-PCR analysis with SYBR RT-PCR kit (Ta-
kara). Analysis of miR-367 and KLF4 was calculated using CT (cycle
threshold) value. RT primers for miR-367 were following: 5′-
TTCTCCGAACTTGTCACGTTT-3′ (forward), 5′-ACGTGACACGTTCGGA-
GAATT-3′ (reverse). The small nuclear RNA U6 was used as control. RT
primers for KLF4 were following: 5′-ATCTTTCTCCACGTTCGCGTCTG-3′
(forward) and 5′-AAGCACTGGGGGAAGTCGCTTC-3′ (reverse) [22]. Actin
was used as control, and the primers were following: 5′-TGACGTG-
GACATCCGCAAAG-3′ (forward), 5′-CTGGAAGGTGGACAGCGAGG-3′
(reverse). Each sample was detected in triplicate.
2.4. Apoptosis anaylsis
Cell apoptosis was detected by ﬂow cytometer analysis. When
the cells reached 80% of conﬂuence, 0.4 μg/ml of ADR was added
for 24 h. Then the cells were digested using trypsin without EDTA
at 37 °C. Wash these cells with cold PBS for three times. Then the
cells were stained with FITC-conjugated annexinV reagent
(2.0 mg/ml) and PI (5 mg/ml) in binding buffer and then were
analyzed by ﬂow cytometer.
2.5. Northern blot assay
The RNA is isolated using Trizol reagent (Takara) followed by the
standard protocol. 20 μg RNA was separated with 15% urea–poly-
acrylamide gel, then electrotransferred to nylon membrane. Hy-
bridization with oligonucleotide probes was performed to detect miR-
367 and U6. The probe sequences were following: 5′-AACTTGT-
CACGTTTACGTTCGGAG-3′ (miR-367), 5′-TGTGGTGCCGGAGCGAGCAG-
3′ (U6). The blots analysis were performed by Fujiﬁlm LAS-4000
system.2.6. Cell transfection
The OS cells were seeded in 6 well-plates at 2105. When the
conﬂuence attained 80%, refreshed the medium without FBS and
transfected 100 nM miR-367 or anti-miR-367 using Lipofectamine
2000 (Invitrogen) for 6 h. Anti-miR-367 (an inhibitor of miR-367),
5′ -UCAACAUCAGUCUGAUAAGCUA-3′; Anti-miR-C (used as a NC
for anti-miR-367 in the antagonism experiment), 5′-GUG-
GAUAUUGUUGCCAUCA-3′. Then refresh the mediumwith 10% FBS.
After incubation for 24 h, treated cells with ADR and harvested the
cells with cold PBS, stored at 80 °C for the following analysis.
2.7. Western blot analysis
Cells were lysed in RIPA buffer with appropriate concentration
of protease inhibitor cocktails (Roche). The supernatants were
obtained and measured by BCA Protein Assay Kit (Pierce). 20 μg of
protein samples were subjected to SDS-PAGE, then transferred
onto PVDF membranes. After incubation with 5% of skim milk, the
membranes were incubated with anti-β-actin (1:2000, Cell Sig-
naling Technology), anti-KLF4 (1:1000, Cell Signaling Technology),
anti-Bax (1:1000, Cell Signaling Technology), anti-caspase-3
(1:1000, Cell Signaling Technology), anti-cleaved caspase-3
(1:1000, Cell Signaling Technology) antibodies at 4 °C over night.
The HRP-labeled secondary antibodies were incubated for 1 h at
RT. The results were detected using Fujiﬁlm LAS-4000 system.
2.8. Luciferase reporter assay
The wild type and mutant 3′UTR of KLF4 were cloned into
PGL3-basic vector. The plasmids were transfected into MG-63 cells
using lipofectamine 2000 reagent (Invitrogen). The miR-367 was
co-transfected at the same time. The normalizing control was pRL-
SV40 plasmid (Promega). After incubation for 24 h, cells were
harvested to detect the activities of luciferase using Dual-Lucifer-
ase Reporter Assay System (Promega).
2.9. Statistical analysis
All of the data were represented as mean7SEM for at least
three repeated experiments for each group. Data were analyzed
using SPSS 17.0 software (SPSS). The comparison between two
groups were conducted by Student's non-paired t-test, and the
comparison of multiple groups were conducted by one-way ana-
lysis of variance (ANOVA). Values of Po0.05 were considered to be
statistically signiﬁcant.3. Results
3.1. Expression of miR-367 was increased in osteosarcoma and cell
cultures
The expression of miR-367 was analyzed in osteosarcoma tis-
sues and OS cells by RT-PCR. As shown in Fig. 1A, expression of
miR-367 was signiﬁcantly increased in osteosarcoma tissues
compared with osteoblast from 40 patients (Po0.01). Meanwhile,
miR-367 was also increased in OS cells MG-63, U2OS and Saos-2
compared with normal osteoblastic cell line HOB (Po0.01, vs. HOB
group, respectively) (Fig. 1B). These data demonstrated that miR-
367 was upregulated in osteosarcoma tissues and OS cell lines.
3.2. ADR induced apoptosis in osteosarcoma cells via suppressing
miR-367
To investigate whether miR-367 was involved in the apoptosis
Fig. 1. Expression of miR-367 was increased in osteosarcoma tissues and cell lines. A. Expression of miR-367 increased obviously in osteosarcoma tissues compared to
osteoblast (**Po0.01). B. Expression of miR-367 increased in OS cell lines Saos-2, MG-63 and U2OS compared to osteoblasts (HOB) (**Po0.01, respectively). Expression of
miR-367 was calculated and normalized to U6 small RNA.
Fig. 2. ADR induced apoptosis in osteosarcoma cells and suppressed miR-367. A–B. Apoptotic rate was detected with ﬂow cytometry analysis of the Annexin V staining in
MG-63 and U2OS cells treated with 0.4 μg/ml ADR for indicated time (MG-63: *Po0.05, **Po0.01; U2OS: #Po0.05, ##Po0.01, respectively). ADR induced apoptosis in a
time-dependent manner. C. Expression of miR-367 were detected by northern blot analysis in MG-63 and U2OS cells with ADR treatment for indicated time. D. RT-PCR were
performed to determine expression of miR-367 in MG-63 and U2OS cells (MG-63: *Po0.05, **Po0.01; U2OS: #Po0.05, ##Po0.01, respectively).
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367 after the treatment of ADR in a time-dependent manner. As
shown in Fig. 2A, ADR induced signiﬁcant apoptosis in MG-63 (6 h,
Po0.05; 12 h, Po0.01; 24 h, Po0.01, vs. 0 h group, Fig. 2B) and
U2OS (6 h, Po0.01; 12 h, Po0.01; 24 h, Po0.01, vs. 0 h group,
Fig. 2B) cells by ﬂow cytometer analysis. Together, Northern blots
(Fig. 2C) and quantitive analysis (Fig. 2D) showed the decreased
expression of miR-367 in a time-dependent manner in MG-63(6 h, Po0.05; 12 h, Po0.01; 24 h, Po0.01, vs. 0 h group) and
U2OS (6 h, Po0.05; 12 h, Po0.05; 24 h, Po0.01, vs. 0 h group)
cells. RT-PCR analysis further supported the results (Fig. 2E)
(MG63: 6 h, Po0.05; 12 h, Po0.01; 24 h, Po0.01, vs. 0 h group;
U2OS: 6 h, Po0.05; 12 h, Po0.05; 24 h, Po0.01, vs. 0 h group).
The data demonstrated that miR-367 was involved with the
treatment of ADR and suppressed by ADR.
Fig. 3. KLF4 was a direct target of miR-367. A. Sequence of KLF4 3′UTR carrying wild type and mutant miR-367 binding site. B. Luciferase reporter assay in MG-63 cells. The
cells was co-transfected with miR-367 and wild type (WT) or mutant type (MT) KLF4 3'UTR. The luciferase activities were measured after 24 hours (Po0.05, KLF-WT vs. NC
group). C. Expression of miR-367 and KLF4 mRNA level. MG-63 and U2OS cells were transfected with miR-367 and RT-PCR were performed after the transfection for 24 h.
Expression of KLF4 decreased due to miR-367 (KLF4: *Po0.05 in MG-63 cells, #Po0.05 in U2OS cells, miR-367 vs. NC group, respectively). D. Expression of KLF4 in MG-63
and U2OS cells. Overexpression of miR-367 suppressed the expression of KLF4. E. Relative density analysis of western blots in D (MG-63: **Po0.01; U2OS: #Po0.05, miR-
367 vs. NC group, respectively).
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To further investigate the function of miR-367 in ADR-induced
apoptosis, we found that KLF4 was probably a direct target of miR-
367 by TargetScan (Fig. 2A), which could facilitate apoptosis via
regulating Bax and Bcl-2. To demonstrate the prediction, we con-
structed the luciferase activity of vector carrying the wild type or
the mutant 3′-UTR of KLF4, as shown in Fig. 2B, miR-367 obviously
reduced the luciferase activities of vector carrying wild type 3′UTR
of KLF4 (Po0.05), while it had almost no inﬂuence on the mutant
3′UTR of KLF4 (P40.05), thus suggested that miR-367 could in-
teract with the 3′UTR of KLF4. Furthermore, overexpression of
miR-367 in MG-63 and U2OS cells distinctly reduced the expres-
sion of KLF4 (MG-63: Po0.05, vs. NC group; U2OS: Po0.05, vs. NC
group) (Fig. 2C). Western blots also showed miR-367 decreased
expression of KLF4 (Fig. 2D) in MG-63 and U2OS cells. The results
demonstrated that miR-367 suppressed KLF4 by interacting with
3′UTR, and suggested that miR-367 might be involved in OS
apoptosis via regulating KLF4 (Fig. 3).
3.4. miR-367 negatively modulated the apoptosis induced by ADR
via regulating KLF4
miR-367 directly targeted on KLF4, which was a deﬁnite anti-on-
cogene according to a variety of previous researches. To clarify the
function of miR-367 and KLF4 in ADR induced apoptosis in OS, MG-63
and U2OS cells were transfected with miR-367 or anti-miR-367, then
the cells were treated with ADR for 24 h. As showed in Fig. 4A and B,
ADR induced signiﬁcant apoptosis in MG-63 and U2OS cells (Po0.01,
ADR/NC vs. Con/NC group, respectively); anti-miR-367 also induced
signiﬁcant increase of apoptotic rate in Con/miR-367 group compared
to Con/NC group in OS cells (Po0.01, respectively). Moreover, anti-
miR-367 obviously enhanced the apoptosis induced by ADR (Po0.01,
ADR/miR-367 vs. ADR/NC groups, respectively), suggesting that miR-
367 acted as an oncogene which could inhibit the apoptosis.Bax was a direct target of KLF4, which signiﬁcantly induced
apoptosis in mammalian cells through activating caspase-3
[23,24]. Western blots analysis showed (Fig. 4B) that ADR treat-
ment increased the expression of KLF4, caspase-3, Cleaved cas-
pase-3 and Bax expression in MG-63 and U2OS cells. Over-
expression of miR-367 not only inhibited KLF4, Bax and Cleaved
caspase-3, but also blocked the effective treatment of ADR in OS
cells (Fig. 4C and E). The results suggested that miR-367 promoted
the resistance of MG-63 and U2OS cells to ADR. In contrast, anti-
miR-367 increased the expression of KLF4, Bax and Cleaved cas-
pase-3, moreover, which were enhanced by combining with ADR
in OS cells (Fig. 4D and F). Thus indicated that anti-miR-367 en-
hanced the sensibility of MG-63 and U2OS cells to ADR. In sum-
mary, these data showed that miR-367 suppressed the apoptosis
induced by ADR via the regulation of KLF4, and suggested that
miR-367 enhanced the resistance of OS cells to ADR.4. Discussion
Discovery and developing novel therapeutic target and strategy
against osteosarcoma remains less optimistic. Recently, miRNAs
have been investigated to regulate diverse physiological and pa-
thological progression, even the tumorigenesis [13,25]. Though
accumulating evidences show that miRNAs participate in tumor
initiation and progression by regulating their target genes, how-
ever, their functions have not been fully understood. Previous
studies showed that miR-367 acted multiple functions in different
kinds of cancer by targeting different genes through inhibiting or
promoting cellular invasion and metastasis [20,21,26]. However,
the expression of miR-367 and its function in OS is little known. In
our study, we conﬁrmed that miR-367 increased in osteosarcoma
and OS cell lines, indicating that miR-367 could be an oncogene in
OS.
Our data also demonstrated that miR-367 was involved in ADR-
Fig. 4. miR-367 modulates resistance of osteosarcoma cells to ADR. A and B. Flow cytometer analysis was used to determine the effect of anti-miR-367 on apoptosis of MG-
63 and U2OS cells with or without treatment of ADR. Anti-miR-367 enhanced the apoptosis induced by ADR (MG-63: **Po0.01; U2OS: ##Po0.01, vs. Con/NC group or the
indicated group, respectively). C and D. Western blots detected the effect of miR-367 or anti-miR-367 overexpression on the expression of KLF4, Bax and caspase3 in MG-63
and U2OS cells with or without treatment of ADR. E and F. Relative density analysis of western blots in C and D, respectively (MG-63: *Po0.05, **Po0.01; U2OS: #Po0.05,#
#Po0.05, vs. Con group or indicated group, respectively).
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drug applied in kinds of malignant cancers [27,28]. ADR induced
OS cells apoptosis, meanwhile, decreased the expression of miR-
367. To further investigate the role of miR-367 on regulating of the
apoptosis, we found KLF4, a tumor suppressor gene which could
facilitate apoptosis [29,30], could be a direct target of miR-367 in
OS cells. Luciferase reporter system was constructed to verify the
interaction of miR-367 and the 3'UTR of KLF4. The results showed
that miR-367 binded to the 3'UTR of KLF4, indicating that KLF4
was regulated at the translational level by miR-367. We also foundthat overexpression of miR-367 suppressed the expression of KLF4
at mRNA and protein level. Deﬁnitive evidences in Fig. 4 showed
transfection of anti-miR367 induced apoptosis, increased KLF4
expression, and also enhanced the sensitivity to ADR in OS cells, all
which were reversed by overexpression of miR-367. Thus strongly
demonstrated miR-367 acted as an oncogene in OS, and could be
involved with the chemotherapy resistance of OS. These ﬁndings
also suggested KLF4 might play the key role in miR-367-involved
cellular proliferation and anti-apoptosis in OS.
Depending on the target gene, KLF4 may function as both a
G.-C. Wang et al. / Journal of Bone Oncology 5 (2016) 51–5656repressor and activator of transcription [31,32]. Previous studies
demonstrated Bax could be a tumor-suppressor target of KLF4
functioning as an anti-oncogene [33,34]. When transfected with
anti-miR-367, MG-63 and U2OS cells showed enhanced sensitivity
to ADR, with up-regulation of KLF4, Bax and activation of caspase-
3, which were also negatively regulated by miR-367 over-
expression. These data suggested that ADR induced apoptosis in
OS cells through the regulation of KLF4 via miR-367, then the pro-
apoptosis factor Bax and cleavage of caspase-3 could lead to ﬁnal
apoptosis.
In summary, our data demonstrates that miR-367 functions as
an oncogene in OS targeting the tumor suppressor KLF4; ADR in-
duces apoptosis in MG-63 and U2OS via the regulation of miR-367/
KLF4/Bax signaling pathway; miR-367 enhances the chemotherapy
resistance of ADR to OS cells through suppressing KLF4. Our data
shows that miR-367 could be a potential biomarker of che-
motherapy resistance and therapeutic target against OS.Acknowledgments
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